Next Gen Diagnostics (NGD), a renowned name in the healthcare industry, has recently made a significant strategic move towards improving infection prevention in healthcare settings. The company announced the appointment of Karlyn Dauplaise as the Chief Commercial Officer (CCO) of NGD Infection Prevention, a newly formed division of the firm dedicated to completely revolutionizing the way hospitals detect and prevent the spread of infections.
Dauplaise, an acclaimed healthcare strategy and performance improvement leader, will be at the helm of the commercial strategy, market development and customer partnerships for NGD Infection Prevention. Her prime objective is to expedite the integration of NGD’s automated Whole Genome Sequencing (WGS)-based, real-time transmission detection solutions into hospital systems. Her leadership is poised to redefine how Integrated Delivery Networks (IDNs) deploy genomic surveillance, which can effectively reduce preventable harm, increase patient safety, and boost operational and financial performance in healthcare establishments.
This transformative approach promises to enhance traditional infection prevention efforts, leveraging advanced genomic technology to track and curtail the transmission rates of potential infections. By championing this innovation, Dauplaise and NGD are stepping into the future of infection prevention, demonstrating their commitment to driving positive change in the healthcare sector.
Preserving personal safety protocols, providing accurate, timely information and showcasing consistent respect for all individuals, are ethical standards that surround the reporting of this assignment. In alignment with that, all input and suggestions related to our work are highly valued.